The triple-agonist everyone's watching against the dual-agonist you can actually get today. What the trial signal shows, and what 'investigational' really means.
In trials, drives the largest average body-weight reduction seen to date for the class (reported ~24–29%).
Grade B, large Phase-3 trial data (TRIUMPH), figures pending peer review; re-verify.
Long-term safety and durability are not yet established; the trial program is ongoing and figures may change at peer review and approval.
Supports the largest average weight loss and metabolic improvement seen in randomized trials to date.
Grade A, large randomized controlled trials (SURMOUNT / SURPASS).
Head-to-head long-term outcome data is still maturing; compounded-formulation specifics differ from the studied branded product.
Tirzepatide is available now under a clinician; retatrutide is an investigational triple agonist still in trials, not available to prescribe, and not something to source grey-market. The early signal for retatrutide is striking, but 'striking phase-2 data' is not 'approved, available, or proven durable.' If you want a supervised path now, the conversation is tirzepatide; retatrutide is one to track.
Retatrutide is investigational, no FDA approval, no legitimate compounded route, and unknown long-term safety. Impressive trial numbers are not a product you can buy. We track its status honestly rather than imply access.
No. Retatrutide is investigational and not FDA-approved; there is no legitimate compounded route. Anything sold as retatrutide today is research-grade / grey-market. Tirzepatide is the available, supervised option.
Early-phase trials suggest large weight loss, but the data is younger and not outcome-mature, and it isn't available. Tirzepatide has grade-A randomized data and a supervised path now.